Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like Analgesic Solutions Presents Data On The Use Of MADDERS To Assess Potentially Abuse-Related Events In Clinical Trials At The June 18, 2017 3rd Stemline Patient Died in Clinical Trial One Day Before $45 Million Public Offering February 1, 2017 Sarepta Taps Allergan Alum as New CEO June 28, 2017
Analgesic Solutions Presents Data On The Use Of MADDERS To Assess Potentially Abuse-Related Events In Clinical Trials At The June 18, 2017
3rd Stemline Patient Died in Clinical Trial One Day Before $45 Million Public Offering February 1, 2017
